Rocket Pharmaceuticals (RCKT) jumped over 10% pre-market after the FDA approved its gene therapy Kresladi for severe LAD-I. It is the company's first commercial product and the first approved gene therapy for this rare immune disorder. The approval also earned Rocket a valuable Rare Pediatric Disease Priority Review Voucher.